Currency Tailwinds, Mainstays Help Takeda To Core Growth
Executive Summary
A weak yen and strong mainstays helped Takeda in its fiscal first quarter, enabling Japan's largest pharma company to overcome the impact of a big divestment last year, while several new products got off on the right foot in the US.